

February 5, 2022

Dear BPG Editorial Office and Reviewers:

Thank you for your letter and the reviewers' comments concerning our manuscript, entitled "**Detection of a novel panel of 24 high-frequency mutant genes in gastric cancer based on next-generation sequencing**" (Manuscript NO: 74005). We agree with the transfer of our manuscript to the *World Journal of Clinical Cases*. The comments were all valuable and very helpful for revising and improving our paper, as well as elucidating the purpose guiding our research. We have considered the comments carefully and made corrections that we hope meet with your approval.

The responses to the reviewers' and Editorial Office's comments are as follows:

1. Response to the reviewers' comments

Reviewer #1

Response to comments:

We thank you for your professional review of our manuscript. Although the incidence and mortality rates of gastric cancer are low in the West, it remains the leading cause of cancer-related death. NGS can rapidly identify specific changes in DNA sequences and detect multiple targets simultaneously, such as amplification, deletion, tumour mutational burden (TMB), and microsatellite instability (MSI). The National Comprehensive Cancer Network (NCCN) guidelines (version 1 2022) have affirmed the value and significance of NGS in the treatment of gastric cancer. However, we need to inform patients that the use of NGS could lead to few clinically meaningful responses. We think that patient and their doctors may jointly decide to order a gene panel at no additional cost from the public health care system.

Reviewer #2

Response to comments:

Thank you for your positive comments on our manuscript.

2. Responses to the Editorial Office's comments

Science Editor

Response to comments:

Thank you very much for the careful reading of our manuscript. We apologize for the spelling errors. Although we have corrected the mistakes according to your comments, we also invited American Journal Experts to further polish our article.

Editorial Office Director and Company Editor-in-Chief

Response to comments:

Thank you again for your positive comments and valuable suggestions to improve the quality of our manuscript. We agree to transfer our manuscript to the *World Journal of Clinical Cases*.

If you have any more questions or concerns, please feel free to contact me. I look forwards to being of service.

Thank you for your consideration.

Sincerely,
Meng Xu

Meng Xu MD,PhD.

Corresponding author

Department of Oncology, The First Affiliated Hospital of Jinan University, Jinan University

Guangzhou, Guangdong Province, 51063, China

Tel: +86 13392692169

Email: 641704010@qq.com